Business Description
Amphastar Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US03209R1032
Total Employee Number:
1,976Compare
Compare
Traded in other countries / regions
AMPH.USA29A.Germany Index Membership
Russell 2000Russell 3000 IPO Date
2014-06-25Description
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.43 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.89 | |||||
Debt-to-EBITDA | 3.56 | |||||
Interest Coverage | 4.53 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.2 | |||||
Beneish M-Score | -2.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 16.2 | |||||
3-Year EBITDA Growth Rate | 16.5 | |||||
3-Year EPS without NRI Growth Rate | 18.2 | |||||
3-Year FCF Growth Rate | 25.7 | |||||
3-Year Book Growth Rate | 16.3 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 4.2 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.23 | |||||
9-Day RSI | 46.14 | |||||
14-Day RSI | 48.37 | |||||
3-1 Month Momentum % | -9.78 | |||||
6-1 Month Momentum % | -30.27 | |||||
12-1 Month Momentum % | -21.76 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.85 | |||||
Quick Ratio | 2.82 | |||||
Cash Ratio | 1.78 | |||||
Days Inventory | 175.13 | |||||
Days Sales Outstanding | 72.52 | |||||
Days Payable | 39.12 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 1.7 | |||||
Shareholder Yield % | 7.94 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 47.34 | |||||
Operating Margin % | 16.2 | |||||
Net Margin % | 11 | |||||
EBITDA Margin % | 26.79 | |||||
FCF Margin % | 18.45 | |||||
OCF Margin % | 23.44 | |||||
ROE % | 10.3 | |||||
ROA % | 4.84 | |||||
ROIC % | 7.49 | |||||
3-Year ROIIC % | 3.56 | |||||
ROC (Joel Greenblatt) % | 24.12 | |||||
ROCE % | 8.83 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 11.84 | |||||
Forward PE Ratio | 7.33 | |||||
PE Ratio without NRI | 9.1 | |||||
Shiller PE Ratio | 14.9 | |||||
Price-to-Owner-Earnings | 11.15 | |||||
PEG Ratio | 0.2 | |||||
PS Ratio | 1.29 | |||||
PB Ratio | 1.13 | |||||
Price-to-Tangible-Book | 4.1 | |||||
Price-to-Free-Cash-Flow | 6.99 | |||||
Price-to-Operating-Cash-Flow | 5.51 | |||||
EV-to-EBIT | 9.81 | |||||
EV-to-EBITDA | 6.53 | |||||
EV-to-Revenue | 1.75 | |||||
EV-to-FCF | 9.49 | |||||
Price-to-GF-Value | 0.4 | |||||
Price-to-Projected-FCF | 0.43 | |||||
Price-to-DCF (Earnings Based) | 0.29 | |||||
Price-to-DCF (FCF Based) | 0.22 | |||||
Price-to-Median-PS-Value | 0.41 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.36 | |||||
Price-to-Graham-Number | 1.29 | |||||
Earnings Yield (Greenblatt) % | 10.19 | |||||
FCF Yield % | 15.34 | |||||
Forward Rate of Return (Yacktman) % | 31.63 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AMPH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Amphastar Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 720.53 | ||
| EPS (TTM) ($) | 1.66 | ||
| Beta | 1.3417 | ||
| 3-Year Sharpe Ratio | -0.43 | ||
| 3-Year Sortino Ratio | -0.66 | ||
| Volatility % | 61.31 | ||
| 14-Day RSI | 48.37 | ||
| 14-Day ATR ($) | 0.963269 | ||
| 20-Day SMA ($) | 19.95675 | ||
| 12-1 Month Momentum % | -21.76 | ||
| 52-Week Range ($) | 16.645 - 31.2641 | ||
| Shares Outstanding (Mil) | 44.09 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Amphastar Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Amphastar Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 14:00 | In 127 days | ||
| Third quarter earnings results for 2026 | 2026-11-06 | In 126 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 14:00 | In 36 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 35 days | ||
| Guidance call for 2026 | 2026-06-03 16:55 | 18.45 (+0.49%) | ||
| General meeting for 2026 | 2026-06-01 11:30 | 18.85 (-2.26%) | ||
| Guidance call for 2026 | 2026-05-13 15:00 | 17.50 (-4.94%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 14:00 | 23.90 (+1.70%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 23.90 (+1.70%) | ||
| 25th Annual Needham Healthcare Conference | 2026-04-14 11:45 | 21.36 (+5.90%) |
Show
Entries
Amphastar Pharmaceuticals Inc Frequently Asked Questions
What is Amphastar Pharmaceuticals Inc(AMPH)'s stock price today?
The current price of AMPH is $19.66. The 52 week high of AMPH is $31.26 and 52 week low is $16.65.
When is next earnings date of Amphastar Pharmaceuticals Inc(AMPH)?
The next earnings date of Amphastar Pharmaceuticals Inc(AMPH) is 2026-08-07 Est..
Does Amphastar Pharmaceuticals Inc(AMPH) pay dividends? If so, how much?
Amphastar Pharmaceuticals Inc(AMPH) does not pay dividend.
Guru Commentaries on NAS:AMPH
No articles.
Press Release
Articles on Amphastar Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers